Three recent clinical updates illustrate the opportunities and challenges facing next-generation oncology therapies. ADC Therapeutics reported positive efficacy data for Zynlonta...

ADC Arms Race Accelerates: Lilly and Gilead Double Down on Next-Generation Oncology Platforms. Acquisitions of CrossBridge and Tubulis highlight how antibody-drug conjugates are becoming a central pillar of oncology pipeline strategy.